A First-in-Human clinical trial evaluating AVZO-1418/DB-1418
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs DB 1418 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 13 Jan 2025 New trial record
- 07 Jan 2025 According to Avenzo Therapeutics, Inc media release , IND-enabling studies are ongoing with plans to advance AVZO-1418/DB-1418 into a first-in-human clinical study this year.